OncoMatch/Clinical Trials/NCT05992220
Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
Is NCT05992220 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Atezolizumab plus bevacizumab for hepatocellular carcinoma.
Treatment: Atezolizumab plus bevacizumab — The recent global IMbrave150 study evaluated the combination of atezolizumab and bevacizumab versus sorafenib in 501 patients with advanced or metastatic Hepatocellular Carcinoma (HCC). The median overall survival (OS) was notably better in the atezolizumab/bevacizumab group. However, for HCC patients with intrahepatic macrovascular invasion (MVI), the prognosis remains poor, indicating a significant unmet need in this group. External Beam Radiotherapy (EBRT) has shown promising results in treating HCC with MVI, especially when used in combination with trans-arterial chemoembolization (TACE). It has been reported that radiotherapy may make tumor cells more susceptible to immune-mediated therapy, potentially enhancing the effects of atezolizumab and bevacizumab. Thus, this study aims to investigate the efficacy and safety of atezolizumab/bevacizumab alone versus atezolizumab/bevacizumab in combination with EBRT in HCC patients with macrovascular invasion.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Hepatocellular Carcinoma Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL; Absolute neutrophil count ≥ 1,000 /mm3; Platelet ≥ 50,000/ mm3 without transfusion
Liver function
Child-Pugh class A hepatic function; Total bilirubin ≤ 2.5 mg/dL
Child-Pugh class A hepatic function; Hemoglobin ≥ 9.0 g/dL; Absolute neutrophil count ≥ 1,000 /mm3; Platelet ≥ 50,000/ mm3 without transfusion; Total bilirubin ≤ 2.5 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify